A Phase 1/2 Study of Venetoclax in Combination With Low-Dose Cytarabine in Treatment-Naive Subjects With Acute Myelogenous Leukemia Who Are ≥ 60 Years of Age and Who Are Not Eligible for Standard Anthracycline-Based Induction Therapy

Trial Profile

A Phase 1/2 Study of Venetoclax in Combination With Low-Dose Cytarabine in Treatment-Naive Subjects With Acute Myelogenous Leukemia Who Are ≥ 60 Years of Age and Who Are Not Eligible for Standard Anthracycline-Based Induction Therapy

Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 21 Aug 2017

At a glance

  • Drugs Venetoclax (Primary) ; Cytarabine
  • Indications Acute myeloid leukaemia
  • Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
  • Sponsors AbbVie
  • Most Recent Events

    • 28 Jul 2017 According to a Roche media release, the US FDA has granted breakthrough therapy designation for Venclexta (venetoclax) in combination with low dose cytarabine (LDAC) for elderly patients with previously untreated AML who are ineligible for intensive chemotherapy. The designation was granted based on data from this trial.
    • 25 Jun 2017 Updated safety and efficacy results from the RP2D 600-mg dose cohorts (n=61, data cut-off Aug 2016) of this study, presented at the 22nd Congress of the European Haematology Association.
    • 12 Jun 2017 According to an AbbVie media release, data from this trial will be presented at the 22nd European Hematology Association Congress.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top